Journal of Interventional Cardiac Electrophysiology

, Volume 40, Issue 1, pp 33–38

Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation

  • Gevorg Stepanyan
  • Nitish Badhwar
  • Randall J. Lee
  • Gregory M. Marcus
  • Byron K. Lee
  • Zian H. Tseng
  • Vasanth Vedantham
  • Jeffrey Olgin
  • Melvin Scheinman
  • Edward P. Gerstenfeld
Article

DOI: 10.1007/s10840-014-9888-9

Cite this article as:
Stepanyan, G., Badhwar, N., Lee, R.J. et al. J Interv Card Electrophysiol (2014) 40: 33. doi:10.1007/s10840-014-9888-9

Abstract

Background

The new oral anticoagulants (NOAC), dabigatran and rivaroxaban, have been demonstrated to be at least equivalent to warfarin for preventing cardiac thromboembolism (TE) in patients with atrial fibrillation (AF). However, there is limited data regarding use around catheter ablation (CA) procedures.

Objective

We evaluated the risk of bleeding and TE complications associated with NOAC use during AF ablation.

Methods

Consecutive patients undergoing AF ablation between January 2011 and 6 September 2013 were grouped based on peri-procedural anticoagulation regimen: (1) uninterrupted warfarin with therapeutic INR (WARF), n = 114, (2) dabigatran, n = 89, or (3) rivaroxaban, n = 98. NOACs were held for 24 h (dabigatran) or 36 h (rivaroxaban) prior to the procedure. Heparin infusion was initiated 6 h post-procedure for the NOAC groups; NOACs were resumed the morning after the procedure. Antral PVI was performed with activated clotting time (ACT) maintained >300 s. TE or bleeding complications during ablation and through 30 days were compared.

Results

Three hundred and one patients underwent ablation for paroxysmal (71 %) or persistent (29 %) AF. International Normalization Ratio (INR) for the WARF group was 2.0 ± 0.5. Baseline characteristics were similar among the groups. There were two TE events (asymptomatic cerebral emboli and TIA), and there were 17 bleeding events (large hematoma n = 4; pericardial effusion n = 6; persistent hematuria n = 1; pseudoaneurism/AV fistula n = 6). Of the six pericardial effusions, three required drainage. There was no significant difference in combined TE/bleeding risk among the groups (WARF vs. dabigatran vs. rivaroxaban; 6.2 % vs. 6.7 % vs. 6.0 %; p = 0.82)

Conclusions

In this group of AF patients undergoing CA, use of peri-procedure dabigatran or rivaroxaban compared to uninterrupted warfarin did not lead to an increase in bleeding or TE complications.

Keywords

Atrial fibrillationAnticoagulationCatheter ablationStrokePulmonary vein isolation

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Gevorg Stepanyan
    • 1
  • Nitish Badhwar
    • 1
  • Randall J. Lee
    • 1
  • Gregory M. Marcus
    • 1
  • Byron K. Lee
    • 1
  • Zian H. Tseng
    • 1
  • Vasanth Vedantham
    • 1
  • Jeffrey Olgin
    • 1
  • Melvin Scheinman
    • 1
  • Edward P. Gerstenfeld
    • 1
  1. 1.Division of Cardiology, Department of MedicineUniversity of California, San FranciscoSan FranciscoUSA